argenex (NASDAQ:ARGX) Stock Bought by Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of argenex SE (NASDAQ:ARGX). In a filing disclosed on November 10th, the Representative disclosed that they had bought between $15,001 and $50,000 in argenex stock on October 14th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 11/2/2026.
• Purchased $1,001 – $15,000 in shares of argenex (NASDAQ:ARGX) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Illumina (NASDAQ:ILMN) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Revvity (NYSE:RVTY) on 10/27/2026.
• Sold $15,001 – $50,000 in shares of PTC (NASDAQ:PTC) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of BridgeBio Pharma (NASDAQ:BBIO) on 10/27/2026.
• Purchased $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 10/27/2026.
• Sold $1,001 – $15,000 in shares of Micron Solutions (OTCMKTS:MICR) on 10/21/2026.
• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/21/2026.
• Purchased $1,001 – $15,000 in shares of ServiceNow (NYSE:NOW) on 10/21/2026.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $977.58 on Thursday. The stock has a market capitalization of $61.48 billion, a price-to-earnings ratio of 34.11, a PEG ratio of 0.90 and a beta of 0.48. The stock’s 50-day simple moving average is $927.22 and its two-hundred day simple moving average is $859.56. argenex SE has a 52-week low of $661.85 and a 52-week high of $1,072.75.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Friday, October 23rd. The company reported $7.80 EPS for the quarter, beating the consensus estimate of $7.44 by $0.36. argenex had a net margin of 31.66% and a return on equity of 47.70%. The firm had revenue of $1.75 billion during the quarter. As a group, equities analysts forecast that argenex SE will post 28.41 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ARGX shares. Truist Financial raised their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Oppenheimer reduced their target price on shares of argenex from $1,100.00 to $1,038.00 and set an “outperform” rating for the company in a report on Monday, October 12th. Royal Bank Of Canada decreased their price target on shares of argenex from $1,100.00 to $1,025.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 20th. Wall Street Zen downgraded shares of argenex from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th. Finally, Robert W. Baird lifted their price target on shares of argenex from $823.00 to $861.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,158.76.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC grew its stake in shares of argenex by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after acquiring an additional 83,568 shares during the period. Jennison Associates LLC raised its stake in argenex by 3.4% during the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock worth $173,411,000 after acquiring an additional 7,707 shares during the period. Allspring Global Investments Holdings LLC raised its stake in argenex by 1.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock worth $130,277,000 after acquiring an additional 2,579 shares during the period. First Trust Advisors LP lifted its holdings in argenex by 98.9% during the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after purchasing an additional 53,293 shares in the last quarter. Finally, Jefferies Financial Group Inc. lifted its holdings in argenex by 55.3% during the third quarter. Jefferies Financial Group Inc. now owns 70,000 shares of the company’s stock valued at $67,124,000 after purchasing an additional 24,932 shares in the last quarter. 60.32% of the stock is owned by hedge funds and other institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About argenex

argenx SE is a global immunology company focused on developing medicines for autoimmune diseases. Founded in 2008 and headquartered in the Netherlands, the company uses antibody engineering and other research approaches to identify and develop treatments for conditions with significant unmet medical needs. Its lead medicine is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo. These products target the neonatal Fc receptor (FcRn) and are approved in the United States for certain patients with generalized myasthenia gravis; Vyvgart Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy. argenx continues to study efgartigimod in additional diseases and develop other potential therapies. argenx operates internationally, with commercial activities and research collaborations across multiple markets.